Impact of Donor CMV‐Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Ze Xiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Liver Transplantation, Carcinoma, Hepatocellular, Liver Neoplasms, Cytomegalovirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: This study was supported by the National Key Research and Development Program of China (Grant No. 2021YFA1100502, 2021YFA1100504), Noncommunicable Chronic Dise….
Abstract (Originalsprache)
Studies investigating the impact of donor cytomegalovirus (CMV) positivity on the prognosis of liver transplantation (LT) recipients with HCC are currently lacking. A total of 21 759 eligible LT recipients were identified in the UNOS database between January 2002 and June 2023. The patients were divided into the donor CMV‐seronegative ( n = 7575) and CMV‐seropositive ( n = 14 814) groups. Moreover, the subgroup analyses by recipient age and gender were conducted. All patients were also divided into 18–40 ( n = 271), 40–60 ( n = 9538), and ≥ 60 ( n = 11 950) groups, male ( n = 16 954) and female ( n = 4805) groups, respectively. Patients in the donor CMV‐seropositive group had shorter overall survival (OS) and disease‐free survival (DFS) compared to those in the donor CMV‐seronegative group (both p < 0.001). Donor CMV seropositivity was proved to be a risk factor for OS and DFS (both p = 0.001). Patients receiving CMV‐seropositive liver grafts had shorter OS and DFS in the 40–60 and ≥ 60 groups (all p < 0.05). Patients receiving CMV‐seropositive liver grafts had shorted OS and DFS only in the male group (both p < 0.001). The receipt of donor CMV‐seropositive liver grafts is associated with shorter survival and a higher risk of HCC recurrence in LT recipients with HCC. These adverse effects are influenced by recipient age and gender.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhejiang University School of Medicine, Hangzhou, China.
- State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Ch…
- School of Clinical Medicine, Hangzhou Normal University, Hangzhou, China.
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, China.
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
ORCID-Profile: Xuyong Wei
Förderung
- This study was supported by the National Key Research and Development Program of China (Grant No. 2021YFA1100502, 2021YFA1100504), Noncommunicable Chronic Dise…
Zitieren
APA
Xiang, Z., Song, Y., Li, J., Yu, J., Xu, C., Xu, Y., Shu, W., Fang, X., Su, R., Lu, Z., Zheng, S., Xu, X., Lu, D., & Wei, X. (2025). Impact of Donor CMV‐Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma. Journal of Medical Virology. https://doi.org/10.1002/jmv.70150
Vancouver
Xiang Z, Song Y, Li J, Yu J, Xu C, Xu Y, et al. Impact of Donor CMV‐Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma. Journal of Medical Virology. 2025. doi:10.1002/jmv.70150
BibTeX
@article{Xiang2025,
author = {Xiang, Ze and Song, Yisu and Li, Jiarui and Yu, Jiong and Xu, Chenhao and Xu, Yunyang and Shu, Wenzhi and Fang, Xixi and Su, Renyi and Lu, Zhengyang and Zheng, Shusen and Xu, Xiao and Lu, Di and Wei, Xuyong},
title = {Impact of Donor CMV‐Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70150}
}
EUVIMED